Tags

Type your tag names separated by a space and hit enter

A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Can J Neurol Sci. 1987 Nov; 14(4):576-80.CJ

Abstract

Fifty-one patients were enrolled in a double-blind, parallel group, multicentre study conducted to assess short-term efficacy and tolerance of bromocriptine (Parlodel) or L-DOPA/carbidopa (Sinemet) in patients never treated with amantadine, ergot alkaloids or L-DOPA-based drugs. An attempt to use the lowest effective dose was made. The responder rate for each group was approximately 78%; the mean daily dose for responders was 22.5 mg of bromocriptine or 250 mg of L-DOPA/carbidopa. The overall clinical improvement in each group was 62% (bromocriptine) and 55% (L-DOPA/carbidopa) for neurological assessment and 36% (bromocriptine) and 31% (L-DOPA/carbidopa) for functional disability. Comparison between groups did not show any significant difference for both neurological and disability assessments. The most frequent side effect was nausea (L-DOPA, N = 3; bromocriptine, N = 6).

Authors+Show Affiliations

Jewish General Hospital, Montreal, Canada.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

3319120

Citation

Libman, I, et al. "A Comparison of Bromocriptine (Parlodel) and Levodopa-carbidopa (Sinemet) for Treatment of "de Novo" Parkinson's Disease Patients." The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques, vol. 14, no. 4, 1987, pp. 576-80.
Libman I, Gawel MJ, Riopelle RJ, et al. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. Can J Neurol Sci. 1987;14(4):576-80.
Libman, I., Gawel, M. J., Riopelle, R. J., & Bouchard, S. (1987). A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques, 14(4), 576-80.
Libman I, et al. A Comparison of Bromocriptine (Parlodel) and Levodopa-carbidopa (Sinemet) for Treatment of "de Novo" Parkinson's Disease Patients. Can J Neurol Sci. 1987;14(4):576-80. PubMed PMID: 3319120.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients. AU - Libman,I, AU - Gawel,M J, AU - Riopelle,R J, AU - Bouchard,S, PY - 1987/11/1/pubmed PY - 1987/11/1/medline PY - 1987/11/1/entrez SP - 576 EP - 80 JF - The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques JO - Can J Neurol Sci VL - 14 IS - 4 N2 - Fifty-one patients were enrolled in a double-blind, parallel group, multicentre study conducted to assess short-term efficacy and tolerance of bromocriptine (Parlodel) or L-DOPA/carbidopa (Sinemet) in patients never treated with amantadine, ergot alkaloids or L-DOPA-based drugs. An attempt to use the lowest effective dose was made. The responder rate for each group was approximately 78%; the mean daily dose for responders was 22.5 mg of bromocriptine or 250 mg of L-DOPA/carbidopa. The overall clinical improvement in each group was 62% (bromocriptine) and 55% (L-DOPA/carbidopa) for neurological assessment and 36% (bromocriptine) and 31% (L-DOPA/carbidopa) for functional disability. Comparison between groups did not show any significant difference for both neurological and disability assessments. The most frequent side effect was nausea (L-DOPA, N = 3; bromocriptine, N = 6). SN - 0317-1671 UR - https://www.unboundmedicine.com/medline/citation/3319120/A_comparison_of_bromocriptine__Parlodel__and_levodopa_carbidopa__Sinemet__for_treatment_of_"de_novo"_Parkinson's_disease_patients_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -